The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1551
ISSUE1551
July 16, 2018
Baricitinib (Olumiant) for Rheumatoid Arthritis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Baricitinib (Olumiant) for Rheumatoid Arthritis
July 16, 2018 (Issue: 1551)
The FDA has approved the Janus kinase (JAK) inhibitor
baricitinib (Olumiant – Lilly) for oral treatment of adults
with moderately to severely active rheumatoid arthritis
(RA) that has not responded adequately to one or more
tumor necrosis...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.